ocaliva
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
NICE approves first biliary cholangitis drug in 20 years
March 2, 2017Sales and Marketing Intercept Pharmaceuticals, intercept, liver disease, ocaliva, primary biliary cholangitis
Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence …
EMA grants conditional approval for biliary cholangitis treatment
October 17, 2016Sales and Marketing EMA, intercept, ocaliva, primary biliary cholangitis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced its approval of Intercept’s Ocaliva …
Intercept’s Ocaliva meets primary endpoint in Phase III trial for rare liver disease
August 18, 2016Medical Communications, Research and Development intercept, ocaliva
Intercept Pharmaceuticals have announced the publication of Phase III results published in the New England Journal of Medicine, where Ocaliva …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
